Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | OXER1 | Q8TDS5 | 6/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5239816 | 0.90 | DPP4 (0.50) | DPP4CYP3A4OXER1MAOAMAOB | |
| SCHEMBL7008759 | 0.89 | DPP4 (0.60) | DPP4CYP3A4OXER1MAOAMAOB | |
| SCHEMBL5234673 | 0.89 | DPP4 (0.50) | DPP4CYP3A4PTGS1PTGS2MAOB | |
| Hydrochloric Acid SCHEMBL5232802 | 0.88 | DPP4 (0.58) | DPP4CYP3A4OXER1 | |
| SCHEMBL6695926 | 0.86 | DPP4 (0.45) | DPP4CYP3A4PTGS2OXER1CASR | |
| SCHEMBL5237699 | 0.85 | DPP4 (0.44) | DPP4 | |
| SCHEMBL5238126 | 0.84 | CYP3A4 (0.44) | DPP4CYP3A4OXER1 | |
| SCHEMBL5238403 | 0.84 | DPP4 (0.45) | DPP4CYP3A4CASRMAOAMAOB | |
| SCHEMBL5235448 | 0.84 | DPP4 (0.44) | DPP4OXER1 | |
| SCHEMBL6107545 | 0.83 | DPP4 (0.42) | DPP4CYP3A4OXER1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | DPP4 2/4885CYP3A4 663/4885PTGS1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.